|
has been serving as Director, Product Development since July 2006. He is a 20 year veteran of the pharmaceutical and biotech industries. He had been the director of inflammation and vaccine research at Osel since 2002. He received his doctorate in physiology and pharmacology from UCSD and was a research fellow at Yale University in the laboratories of Jim Jamieson and Nobel laureate Paul Greengard prior to joining Boehringer Ingelheim Pharmaceuticals in 1985. At Boehringer, Dr. Parks spearheaded several discovery programs in inflammation and autoimmune diseases, in the areas of lipid mediators, transcription regulation, and signal transduction, and served on a number of compound development teams. In 1998, Dr. Parks joined Cellegy Pharmaceuticals and served as the director of molecular biology and experimental therapeutics where he established research and drug development programs in the areas of skin inflammation and gastrointestinal diseases. At Osel, Dr. Parks has been involved in the development of genetically modified Lactobacillus as a novel mucosal delivery vehicle for vaccines, anti-toxins, and anti-viral proteins. | 